Signal Radar · SIG-2026-017

ARPA-H ADVOCATE targets FDA-authorized clinical agentic AI for cardiovascular care

96/100 priorityAgentic AI + Clinical CareActive program2026-01-13

ARPA-H's ADVOCATE program is designed to develop clinical AI agents that can autonomously support and adjust aspects of cardiovascular care, alongside a supervisory AI overseer.

Why it matters

This moves agentic AI from administrative copilots toward clinically consequential autonomous actions with explicit safety, efficacy, monitoring, and regulatory requirements.

Decision implication

Create a dedicated agentic-AI adoption standard covering authority boundaries, human escalation, post-deployment monitoring, evidence, liability, workflow, and regulatory status.

Who or what is affected

  • ARPA-H
  • FDA
  • cardiovascular health systems
  • AI developers
  • clinicians
  • patients

Evidence and sources

E5 — official ARPA-H source

P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.

What P4L is watching next

  • Awardees
  • supervisory-agent architecture
  • FDA pathway
  • clinical validation
  • deployment sites.

Related proof records

Last verified: 2026-08-08 · Version 1.0 · Stable ID: SIG-2026-017